EDINBURGH, UK & LONDON, UK, Sept. 1, 2026
Resolution Therapeutics Limited has partnered with Blood Centers of America, Inc. (BCA) to support broad patient access to its experimental Regenerative Macrophage Therapy (RMT), RTX001, as the company prepares for a pivotal clinical program in the United States. The partnership is focused on establishing a community-based treatment and cell collection network that can support clinical trial sites and improve geographic access for patients with end-stage liver disease (ESLD). Under the agreement, BCA will serve as one of Resolution’s preferred providers of cell collection and processing services for participating pivotal study sites requiring this infrastructure. The collaboration is designed to address a key operational challenge for cell therapy development: enabling patients to receive investigational treatment closer to their communities rather than requiring repeated travel to specialized centers.
Resolution Builds U.S. Infrastructure for RTX001
The partnership with BCA represents an important step in Resolution Therapeutics’ preparations for the planned RTX001 pivotal clinical program in 2027. BCA operates a network of member blood centers with broad geographic reach across the United States, providing established capabilities in patient apheresis, cell collection, processing, product handling and storage. These services are particularly relevant for autologous cell therapy programs, where reliable collection and logistics are essential to clinical trial execution. Resolution said the collaboration is intended to help participating healthcare organizations deliver RTX001 in regions where specialized cell therapy infrastructure may otherwise be limited. The company is specifically targeting the community care setting, where many patients with decompensated liver disease are managed. By developing this infrastructure ahead of its pivotal study, Resolution aims to support more practical access to its investigational therapy as clinical development progresses.
RTX001 Designed for Community-Based Treatment
Resolution is developing RTX001 as a differentiated Regenerative Macrophage Therapy for patients with ESLD, a population with substantial unmet medical needs. The experimental therapy is administered through a peripheral intravenous infusion and is designed as a repeat-dose treatment without pre-conditioning, bridging therapy or lymphodepletion. According to the company, these characteristics could reduce some of the logistical complexity associated with other cell therapy approaches and potentially make RTX001 more suitable for administration outside highly specialized treatment centers. Resolution said early clinical studies of RTX001 have not identified significant safety signals to date and have not indicated a requirement for prolonged monitoring. The company is developing RMT as a cell therapy approach intended to modify the disease environment and promote conditions that may support tissue regeneration. Resolution believes RTX001 could potentially provide a disease-modifying option for ESLD patients who face limited treatment alternatives..
Advertisement
Resolution Targets 2027 Pivotal Study
Resolution Therapeutics plans to initiate a pivotal clinical study of RTX001 in end-stage liver disease across the United States in 2027, following a pre-IND meeting with the U.S. FDA. The company will continue working toward finalizing the pivotal study design and selecting specific clinical trial sites as the program advances. The development strategy is centered on generating clinical evidence for RTX001 in a patient population where liver transplantation remains the only established disease-modifying treatment option, while access to transplantation can be limited by donor availability, geographic barriers and the complexity of transplant care. Resolution is positioning its BCA partnership as part of the operational foundation needed to expand participation in the upcoming U.S. pivotal program. Beyond RTX001, the company is advancing additional Regenerative Macrophage Therapy programs in inflammatory and fibrotic diseases, including lung fibrosis, while also developing an in vivo RMT platform currently in preclinical evaluation. The RTX001 program remains the company’s lead clinical focus as Resolution prepares for its next stage of development in 2027.
Source : Resolution Therapeutics,,press relese
